You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Medications Articles
Burnout is common among people with diabetes, especially those who have had the disease for years, even decades. Diabetes management can be exhausting, confusing, and frustrating, particularly when you think you are doing everything right but your blood sugars still fail to cooperate.
0 comments - Posted May 17, 2012
Novo Nordisk's new variety of long-lasting insulin, insulin degludec, reduces low blood sugars while improving overall control, according to a pair of studies published in the prestigious journal The Lancet on April 27.
0 comments - Posted May 8, 2012
Diabetes Health recently submitted some questions to CVS Caremark Corporation regarding its "The State of the States: Adherence Report." The report compiled data from more than 50 million patients to track their level of adherence to drug prescriptions for four chronic diseases: diabetes, depression, high blood pressure, and high cholesterol.
0 comments - Posted May 4, 2012
When people are diagnosed with diabetes, things can seem pretty overwhelming. In a short time, they have to absorb a daunting amount of information and start making significant decisions about the way they live their lives.
0 comments - Posted Sep 3, 2011
With severe weather predicted for Tuscaloosa, Alabama, Meredith Cummings thought carefully about where to park her car-eyeing the large trees in her historic neighborhood-when she arrived home on the afternoon of April 27. As she walked to her door, she reassured herself: Those trees had been there for more than 100 years. What were the odds of them coming down today?
0 comments - Posted Jul 22, 2011
The Internet allows consumers to shop for deals on anything imaginable, even prescription drugs. The economic struggles that many currently face, paired with the increasing cost of healthcare and prescription drugs, have created an environment in which counterfeit drug makers can prosper.
0 comments - Posted Jul 7, 2011
Scandal swirling around a former diabetes drug has upended medical regulation in France, with the country's health minister promising tough new reforms.
0 comments - Posted Mar 1, 2011
New University of Georgia research has found that a statin drug that is often known by the brand-name Lipitor may help prevent blindness in people with diabetes. In a study using diabetic rats, lead author Azza El-Remessy, assistant professor in the University of Georgia College of Pharmacy, and her colleagues found that statins prevent free radicals in the retina from killing nerves important to maintaining vision. The results of the study are published in the March edition of the journal Diabetologia.
0 comments - Posted Feb 23, 2011
Ross Valley Pharmacy, tucked away inside a larger building of clinics, is not a big place, but it's very very busy. Its owner, Paul Lofholm, PharmD, has a vision of the pharmacist's role that goes far beyond simply putting pills in bottles. He sees pharmacists as integral members of the healthcare team who can fill the gaps in patients' education about their conditions and their medications.
0 comments - Posted Feb 21, 2011
Ross Valley Pharmacy, tucked away inside a larger building of clinics, is not a big place, but it's very very busy. Its owner, pharmacist Paul Lofholm, has a vision of the pharmacist's role that goes far beyond simply putting pills in bottles. He sees pharmacists as integral members of the healthcare team who can fill the gaps in patients' education about their conditions and their medications.
0 comments - Posted Feb 20, 2011
Nearly one in six people in the United States has no health insurance. If you have diabetes, that's a very tough position to be in. There are, however, resources that can cut the costs that you have been paying out of pocket for medicines and supplies.
0 comments - Posted Feb 14, 2011
The kuriously named Kombiglyze XR, a combination of Onglyza (saxagliptin) and the old reliable metformin, has arrived at pharmacies and is available by prescription to people with type 2 diabetes. It's similar to Janumet, an older medication that's a combination of Januvia (sitagliptin) and metformin.
0 comments - Posted Jan 25, 2011
Most type 2 meds work by increasing insulin production in one way or another. The extra insulin lowers blood sugar by ushering it out of your bloodstream and into your cells, where it may, unfortunately, make you fat. Wouldn't it be nice if instead, you could lower your high blood sugar by just flushing it right down the toilet?
0 comments - Posted Jan 17, 2011
Sitagliptin (Januvia) has long been used to reduce blood sugar in people with type 2 diabetes, but a new study indicates that it can do the same for those with type 1 diabetes. Sitagliptin is a DPP-4 inhibitor; that is, it inhibits, or temporarily prevents, the enzyme DPP-4 from destroying a helpful hormone called GLP-1. GLP-1, which is released by the gut when food arrives there from the stomach, lowers blood sugar by causing the release of insulin, reducing the secretion of glucagon, and slowing stomach emptying and nutrient absorption.
0 comments - Posted Jan 7, 2011
Arena Pharmaceuticals and Eisai Inc. recently released results of a phase 3 clinical trial for lorcaserin, a weight-loss drug they are developing in partnership. The trial, called BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management- Diabetes Management), targeted patients with type 2 diabetes who are overweight or obese.
0 comments - Posted Dec 28, 2010
A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss.
0 comments - Posted Dec 27, 2010
The newest threat to patient health may not be the flu or other epidemics. It could be a major shortage of prescription drugs. The shortage has reached the level of a "national public health crisis," according to a survey conducted by the Institute for Safe Medication Practices (ISMP) this summer. Survey respondents said shortages in the past year were "the worst ever, without a glimmer of hope for any improvement in the near future."
0 comments - Posted Nov 27, 2010
A new drug for type 2 diabetes started showing up in drugstores this week, according to manufacturer Santarus. The FDA-approved drug, called Cycloset, takes an distinctive -- and not well understood -- approach to reducing blood sugar levels. The pill apparently works by increasing dopamine activity in the hypothalamus, a part of the brain. Dopamine is a brain chemical that plays a big role in people's behavior, mood, and ability to sleep. Scientists theorize that glucose intolerance and insulin resistance may in part result from abnormal activity of this chemical, and that upping dopamine activity may iron out these problems.That's the theory, at least: the drug's exact workings aren't known. But it seems to do the trick.
0 comments - Posted Nov 24, 2010
The Centers for Medicare & Medicaid Services (CMS) is encouraging all Medicare beneficiaries to take advantage of the annual Open Enrollment period to make sure they have the best coverage available to meet their health care needs in 2011.
0 comments - Posted Nov 16, 2010
Dear Diabetes Health, I am 62 years old. I was diagnosed with type 2 diabetes in 1997, and I am doing OK on metformin. My last A1c was 7.2 %. About a year ago, they put me on medicine for my blood pressure (which was 142/90) and for cholesterol. I started having less interest in sex, which I had really liked before.
0 comments - Posted Sep 7, 2010
And wouldn't it be great if that pill weren't something advertised on late-night TV, but rather a legitimate treatment? A drug called rimonabant, introduced in Europe, seemed to fit the bill at first, but it was pulled from the market in late 2008 due to concerns about psychiatric side effects.
0 comments - Posted Aug 10, 2010
A long-term study on the safety of a popular diabetes drug was put on hold Wednesday by the Food and Drug Administration, while the FDA considers whether it's too dangerous to continue. Several large studies have linked the drug, Avandia, to a higher risk of heart attacks and other heart problems. While other studies have not found the same risk, last week an FDA advisory panel recommended that the drug not be sold without a stronger warning label or possibly limits on who could receive it.
0 comments - Posted Jul 23, 2010
(Reuters) - The first new prescription weight-loss pill in more than a decade failed to win backing from U.S.health advisers, who said safety concerns about the drug outweighed its ability to help obese patients shed pounds.
0 comments - Posted Jul 19, 2010
The U.S. Food and Drug Administration's (FDA) Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee has completed their evaluation of the scientific research available on the safety of rosiglitazone. The deliberations of the panel reflected the complexity of the issues, with several members voting to add additional warnings or to withdraw the drug from the U.S. market. Ultimately, the final recommendation was to allow Avandia to remain on the market. Now that the expert panel has concluded its meeting, the FDA will review their recommendations and make the final decision on whether the drug remains available to patients.
0 comments - Posted Jul 15, 2010
A study released in late June has brought some welcome news to the makers of Byetta and Januvia: Users of the two diabetes drugs run no greater risk of developing pancreatitis than people with diabetes who take other drugs. In fact, both drugs seem to put users at slightly less risk for the condition.
0 comments - Posted Jul 8, 2010
AFREZZA TM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented at the American Diabetes Association's 70th Scientific Sessions.
0 comments - Posted Jul 6, 2010
Depomed, Inc. and Santarus, Inc. announced new data suggesting that patients previously intolerant of metformin may be able to tolerate higher doses of metformin when treated with GLUMETZA® (metformin HCl extended release tablets). The finding will be presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando. GLUMETZA is a once-daily, extended release formulation of metformin, and is approved for use in adults with type 2 diabetes mellitus. It is promoted in the U.S. by Santarus.
0 comments - Posted Jul 1, 2010
A Canadian study that tracked 207 patients suggests that a low-dose combination of metformin and Avandia can reduce the development of type 2 diabetes by 66 percent in people at high risk for the condition.
0 comments - Posted Jun 15, 2010
New guidelines from the American Diabetes Association and two other major medical associations advise not prescribing low-dose aspirin therapy for women under 60 or men under 50 who have diabetes but no other risks for heart disease.
0 comments - Posted Jun 12, 2010
Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.¹ In the study, 37 percent of patients treated with MACUGEN gained two lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, compared to 20 percent of patients who received a sham (placebo-like) procedure which consists of anesthesia and a simulated injection in the eye (p=0.0047). The data were presented at the World Ophthalmology Congress in Berlin by Frank G. Holz, an investigator in the trial and director of the University Eye Hospital at the University of Bonn in Germany.
0 comments - Posted Jun 7, 2010
If you take metformin to control your type 2 diabetes, ask your doctor to take a look at your vitamin B-12 levels when you get a chance. A recent British study shows that metformin may cause a deficiency in the vitamin, which is necessary for the regeneration of red blood cells and the maintenance of nervous system health.
0 comments - Posted Jun 5, 2010
The Food and Drug Administration (FDA) has launched a "Bad Ad Program," an outreach effort aimed at educating healthcare providers and urging them to report misleading drug advertisements. The Division of Drug Marketing, Advertising, and Communications (DDMAC), in the FDA's Center for Drug Evaluation and Research, administers the program.
0 comments - Posted May 13, 2010
Scientists at the Mayo Clinic have developed a molecule that can block the breakdown of insulin. Their discovery could lead to development of a new class of drugs to help treat diabetes.
0 comments - Posted May 10, 2010
CINCINNATI - The popular diabetes medication metformin works in different fashion than the current widely accepted view. This new finding could lead to wider use of the drug-particularly in people with cancer.
0 comments - Posted May 4, 2010
Santa Clara County, the largest county in Northern California (nearly 1.9 million people), has filed a federal lawsuit against pharmaceutical company GlaxoSmithKline, alleging that Glaxo knowingly sold its type 2 diabetes drug Avandia for several years despite indications the drug causes heart attacks and strokes.
0 comments - Posted Mar 8, 2010
If you regularly take metformin, one of the oldest and most respected tools in doctors' anti-diabetes kits, chances are that you don't detect the unpleasant odor that turns some type 2s against the drug. Some think it has fishy smell, while others say that it reminds them of the inside of an inner tube.
0 comments - Posted Mar 4, 2010
A U.S. Senate Finance Committee report released on February 20 says that Avandia, GlaxoSmithKline's drug for type 2 diabetes, may have caused as many as 83,000 heart attacks between 1999, when the drug was introduced, and 2007. The Senate report, culminating a two-year inquiry into the drug, also says that Glaxo knew about the drug's potential risks years before suspicions began to form regarding a connection between Avandia and heart problems.
0 comments - Posted Feb 22, 2010
German and Swiss researchers have found that high-density lipoprotein, or HDL-so-called "good" cholesterol-does not protect blood vessels in people with type 2 diabetes as well as it does in people who don't have the disease. However, their follow-up experiment, which added doses of extended-release niacin, shows that HDL's efficacy in type 2s might be sharply increased simply by the addition of a daily niacin pill.
0 comments - Posted Jan 9, 2010
Denmark-based Novo Nordisk A/S has begun phase 1 testing of an insulin pill that, if successful, could replace injections as the primary means of blood sugar control for millions of people with type 1 and type 2 diabetes. The company has enrolled 80 volunteer German test subjects in the study and expects to have preliminary results by the first half of 2011. The test group consists of both people with diabetes and people without it.
0 comments - Posted Dec 24, 2009
WORCESTER, Mass., Dec 3, 2009 (GlobeNewswire via COMTEX News Network) -- Published in the journal Diabetes, Obesity and Metabolism, an independent review of clinical trials of Generex Oral-lyn(TM) shows that the oral insulin spray has a faster onset of action and shorter duration of action than insulin delivered subcutaneously.
0 comments - Posted Dec 9, 2009
ALEXANDRIA, Va. (Dec. 1, 2009) - Seniors may find that many common prescription drugs that Medicare Part D has covered for years may suddenly be denied due to a new policy being implemented by the Centers for Medicare and Medicaid Services (CMS).
0 comments - Posted Dec 3, 2009
The enthusiasm for inhaled insulin has waned, to say the least, since Exubera was pulled off the market by Pfizer. Following the Exubera debacle, the development of two other inhaled insulins (AIR by Eli Lilly and Alkermes, and AERx by Novo Nordisk) was halted as well.
0 comments - Posted Oct 5, 2009
One of the major complications of diabetes is diabetic nephropathy, a loss of kidney function that may lead to renal failure. As kidney disease progresses, the barrier that keeps large molecules out of the urine, called the glomerular barrier, begins to break down. With the barrier failing, certain large molecules begin to migrate into the urine. One of those hefty molecules is immunoglobulin M, or IgM.
0 comments - Posted Aug 19, 2009
The theory of unintended consequences has gotten another boost. Although two drugs designed to slow the loss of kidney function in people with type 1 diabetes turned out to be busts, they had a wonderful but entirely unexpected side effect: Eye damage was reduced by 65 to 70 percent in the patients taking them.
0 comments - Posted Aug 17, 2009
Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP-4) inhibitor produced by AstraZeneca and Bristol-Myers Squibb, has been approved by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
0 comments - Posted Aug 15, 2009
Most clinical studies of new drugs are conducted primarily on white men, whether or not they are most affected by the disease the drug is intended to treat. African Americans, for example, are 1.6 times more likely to have diabetes than non-Hispanic whites. Why should we assume that what works for white males will also be effective for African Americans, Hispanics, Asians, or, for that matter, women?
0 comments - Posted Aug 6, 2009
Metformin is one of the oldest and most tried-and-true diabetes treatments around, but apparently it has a new talent. According to research from the M.D. Anderson Cancer Center at the University of Texas, good ol' metformin reduces a type 2 person's risk of pancreatic cancer by 62 percent.
0 comments - Posted Aug 5, 2009
In April of 2008, our healthy nine-year-old son, Gaspar, was diagnosed with type 1 diabetes. After his two days in the ICU and a week in the hospital, a new life began for all of us. Although we couldn't immediately grasp all its implications and were simultaneously dealing with our shaken world, we gave the situation a "think outside the box" approach. When the endocrinologist told us, "That's the way it is. Just focus on the controls and all will be fine," we asked whether the condition might be cured or attenuated if we acted quickly at the beginning. We were met with the usual answer: "There's nothing you can do. Just focus on the controls."
0 comments - Posted Aug 3, 2009
Of all the quests that researchers have undertaken in search of a cure or decisive treatment for type 1 diabetes, the search for a vaccine has to be the boldest. But how would you develop such a vaccine, and how would it work?
0 comments - Posted Jul 9, 2009
The International Diabetes Federation (IDF) has called for urgent assessment and responses from regulatory authorities into a possible link between the use of insulin glargine (an insulin analog) and increased risk of cancer. The proposed link is based on findings published on June 26, 2009, in Diabetelogia, the journal of the European Association for the Study of Diabetes (EASD).
0 comments - Posted Jul 6, 2009
Genentech, a bioscience firm famous for its development of antibodies designed to combat cancer, has entered a $350 million agreement with Bayhill Therapeutics to assist in development of BHT-3021, a drug that treats type 1 diabetes by reducing or stopping immune system attacks on pancreatic beta cells.
0 comments - Posted Jul 1, 2009
CRx-401, an insulin sensitizer intended to assist metformin in type 2 diabetes therapy, has successfully completed a Phase 2 clinical trial in which patients taking it saw their fasting plasma glucose drop by 12 mg/dl after 90 days.
0 comments - Posted Jun 3, 2009
The U.S. Food and Drug Administration has just approved the marketing of Cycloset, a type 2 diabetes drug that works by affecting a brain chemical that helps govern metabolism. In doing so, it helps reduce the rise in blood sugar levels that typically occurs after meals. Cycloset will be offered as a monotherapy or in conjunction with sulfonylureas, metformin, or other combination type 2 drug therapies.
0 comments - Posted May 12, 2009
The Chinese mentioned cinnamon in their written work more than 4,000 years ago. The ancient Egyptians used cinnamon in their embalming process, and the Roman writer/philosopher Pliny the Elder wrote in the first century AD that cinnamon was worth 15 times more than silver of the same weight.
0 comments - Posted Dec 25, 2008
Avandia (rosiglitazone) and Actos (pioglitazone), two medications used to lower blood sugar in type 2 patients, double the risk of fractures in women, but not in men, says a new study.
0 comments - Posted Dec 22, 2008
As a child, I had an obsessive, irrational fear of going blind. At night, I lay in bed and kept opening my eyes every few minutes as I fell asleep to make sure I could still see, searching for outside lights filtering through the curtains of my bedroom window.
0 comments - Posted Nov 17, 2008
When I was growing up in the South, my mother always told me, "You are what you eat." With Americans leading the pack in obesity and type 2 diabetes, it appears that she may have been right. Years of drive-through dinners and instant breakfasts have caught up with us, making us rethink every bite that passes our lips in our quest to fight off the complications of diabetes.
0 comments - Posted Nov 3, 2008
Novo Nordisk recently announced results from its LEAD 6 study showing that once daily liraglutide was significantly more effective at improving blood glucose control (as measured by A1c) than exenatide, a GLP-1 mimetic administered twice daily.
0 comments - Posted Oct 27, 2008
An aspirin-like drug discovered 132 years ago may prove to be a powerful weapon against type 2 diabetes.
0 comments - Posted Oct 13, 2008
Canadian researchers report that succinobucol, an anti-oxidant drug used to treat cardiovascular inflammation, appears to have a beneficial effect in lowering the risk of developing diabetes. Even patients who already have diabetes, they say, achieve better blood sugar control while on the drug.
0 comments - Posted Jun 19, 2008
”Intense Hydrating Cream” from Pedi-Relax®, a cream made in France and used by people with diabetes in Europe to treat their soles, is now available in the United States at www.cvs.com for $7.99. The line is specifically formulated for extremely dry and damaged feet and is endorsed by the Federation of International Podiatrists.
0 comments - Posted Jun 12, 2008
Dear friends of Diabetes Health,
We value your hard-earned diabetes wisdom and we want you to share it with the world! Please join us as a professional or lay diabetes advisor in one of our Diabetes Health website content Rooms.
0 comments - Posted Jun 6, 2008
Most diabetes drug trials focus strictly on the medication's effect on blood sugar levels, but ignore that medication's impact on other outcomes that are important to patients, such as quality of life and the risk of complications.
0 comments - Posted Nov 22, 2007
Januvia, also known as sitagliptin phosphate, is a DPP-IV inhibitor. It prevents, or inhibits, DPP-IV from inactivating GLP-1. GLP-1 is a naturally produced hormone that increases insulin secretion in response to food.
0 comments - Posted Nov 20, 2007
The Food and Drug Administration (FDA) just approved pre-filled pens for administering Symlin, which was previously available only in vials. The SymlinPen 60 delivers 15, 30, 45, or 60 micrograms per dose.
0 comments - Posted Nov 14, 2007
A recent study has found that the combination of metformin and sitagliptin lowers A1c's better than either drug alone, apparently because their different mechanisms work together synergistically.
0 comments - Posted Nov 12, 2007
The FDA has received thirty reports of acute pancreatitis (rapid-onset inflammation of the pancreas) in type 2 patients taking Byetta. Twenty-seven of the thirty patients had one or more risk factors for acute pancreatitis, such as gallstones or alcohol use.
0 comments - Posted Nov 5, 2007
On one hand, GlaxoSmithKline really, really wants you to take their new over-the-counter diet pill, alli. On the other hand, they don't want you to abandon healthy habits in favor of pill popping.
0 comments - Posted Jul 15, 2007
A study from the Mayo Clinic has found that using a decision-making tool with patients when discussing medication options makes them more likely to take their prescribed medicine.
0 comments - Posted Jun 26, 2007
Patients with diabetes are less likely to have a heart attack or die if they stay on anti-clotting medication for a full year after a stenting procedure.
0 comments - Posted Jun 11, 2007
Thinner artery walls are a good thing, because thicker ones indicate atherosclerosis and an increased risk of heart attack. In a study published in the December 2006 Journal of the American Medical Association, pioglitazone (Actos, a thiazolidinedione) was compared to glimepiride (a sulfonylurea) with regard to carotid artery thickness.
0 comments - Posted Jun 9, 2007
Medco, a pharmacy benefit managing company, has released its 2007 Drug Trend Report, and diabetes drugs are big news. The report projects that between 2007 and 2009, there could be a near 70 percent increase in spending on endocrine and diabetes drugs.
0 comments - Posted Jun 8, 2007
University of California, San Francisco - In head-to-head trials of two drugs, the one deemed better appears to depend largely on who is funding the study, according to an analysis of nearly 200 statin-drug comparisons carried out between 1999 and 2005.
0 comments - Posted Jun 5, 2007
Many heart attacks are caused by platelets sticking together and forming clots that block blood flow. Aspirin reduces clotting by inhibiting an enzyme that helps platelets stick together. But if you have diabetes and are taking low-dose aspirin to prevent platelets from gumming up your blood vessels, your low dose might be a little too low.
0 comments - Posted May 16, 2007
A drug initially designed to treat the autoimmune disease of juvenile rheumatoid arthritis has been found helpful in treating type 2 diabetes. The drug is an “interleukin-1-receptor antagonist” that goes by the name of anakinra (Kineret).
0 comments - Posted May 16, 2007
INDIANAPOLIS Data from a pooled analysis of three studies suggest that in patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta (duloxetine HCl), improvements in both average daily pain and night pain severity were associated with less pain-related sleep interference than in those patients taking sugar pill.
0 comments - Posted May 15, 2007
Have you lost interest in the world around you? Are you more difficult to engage in conversation or in doing chores? Have you lost interest in doing things or in starting new activities? Are you apathetic or indifferent? If your answer to these questions is yes, then you may be suffering from apathy syndrome.
0 comments - Posted Apr 5, 2007
A long-term study published in a recent issue of the Journal of Palliative Medicine found that Eli Lilly’s non-narcotic prescription drug Cymbalta (duloxetine HCl) is as safe and well-tolerated as current routine care that uses one or more medications for the management of pain caused by diabetic nerve damage. Study findings also show that Cymbalta did not adversely affect the progression of diabetes or many of the complications associated with the illness, such as damage to the nerves, kidneys and eyes.
0 comments - Posted Jul 1, 2006
In August 2005, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) had approved ACTOplus Met for the treatment of type 2 diabetes.
0 comments - Posted Nov 1, 2005
Exenatide (synthetic exendin-4) significantly reduced A1C in patients with type 2 diabetes who were failing maximum doses of a sulfonylurea, according to researchers at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, and the Veterans Medical Center at the University of California San Diego. Exenatide was well tolerated and associated with weight loss.
0 comments - Posted Jan 1, 2005
With nearly 20 percent of type 1s and 2s suffering from some form of depressive disorder, depression is an issue of paramount importance for the diabetes community, and one with far-reaching ramifications. The May issue of Diabetes Care reports that a new class of antidepressant agents has just finished its first round of clinical trials, and the results look good.
0 comments - Posted Sep 1, 2000
A six-year study which appeared in the March 30 issue of The New England Journal of Medicine seeks to shed some light on which antihypertension drugs might induce type 2 diabetes.
0 comments - Posted Jan 7, 2000
The Food and Drug Administration (FDA) has identified five new cases of liver failure linked to Rezulin.
0 comments - Posted Sep 1, 1999
Orlistat, brand name Xenical, a new drug for weight loss, has been approved by the Food and Drug Administration. The first of a new class of drugs called lipase inhibitors, Xenical does have some side effects that may be difficult to discuss in polite company.
0 comments - Posted Jul 1, 1999
Rezulin, a type 2 diabetes drug manufactured by Warner-Lambert, has been receiving its fair share of black eyes recently. Many in the diabetes community, however, are standing by Rezulin as an effective agent in treating type 2 diabetes. Others are making plans to treat their type 2 diabetes through other means.
0 comments - Posted Feb 1, 1999
Now impotence sufferers have another valuable ally. VIVUS Inc. has received clearance from the U.S. Food and Drug Administration (FDA) to market its new product MUSE (Alprostadil), a urethral suppository for the treatment of impotence.
0 comments - Posted Feb 1, 1997
Currently there are an estimated 16 million people with diabetes in the United States. Perhaps ten percent are insulin-dependent-the rest have type 2 diabetes, which they control with diet, exercise, oral medications, and insulin.
0 comments - Posted Mar 1, 1996
Though it may be a promising alternative for many people with type 2 diabetes, the drug metformin may cause severe side effects, even death, in some patients.
0 comments - Posted Mar 1, 1995
Dr. Nancy Bohannon is actively involved in diabetes research and operates a full-time private practice in Internal Medicine, specializing in Diabetes and Endocrinology. Recently Dr. Bohannon spoke to Scott King via telephone from her office in San Francisco about current protocols available for predicting and preventing Type 1 diabetes.
0 comments - Posted Nov 1, 1992